Croda International has entered a collaboration agreement with the Access to Advanced Health Institute (AAHI) to innovate and develop vaccine adjuvant formulations.
Under this deal, the parties will use their combined capabilities to make new vaccine adjuvants accessible worldwide. This approach will aid in the advancement of next-generation vaccines that are robust and durable.
Go deeper with GlobalData
The AAHI has platform technologies designed to harness the immune system in fighting diseases.
In addition, the institute has an adjuvant formulation portfolio used in numerous vaccine candidates for fighting major infectious and neglected ailments identified by the World Health Organization (WHO) as global threats.
The exclusive agreement between the AAHI and Croda encompasses joint research and development efforts.
See Also:
By combining their expertise, the parties are set to accelerate the quick development of new adjuvants and formulations.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThey also plan to establish efficient manufacturing processes for large-scale production to meet the demands of the vaccine industry and global health needs.
Under the partnership, Croda will gain specific rights for the marketing, distribution, and sale of selected new adjuvant formulations that are developed by the AAHI.
These formulations are intended for research purposes and clinical development.
Croda will become the AAHI’s exclusive authorised manufacturer in various countries to scale up manufacturing processes, providing support for Phase III trials and commercial usage.
Croda Life Sciences president Daniele Piergentili said: “This partnership marks another significant milestone in our endeavour to offer a comprehensive portfolio of adjuvants for the vaccines of tomorrow.
“It perfectly aligns with our pharmaceutical strategy to ‘Empower biologics delivery’ and underscores our commitment to making substantial contributions to the successful development and commercialisation of WHO-listed pipeline vaccines.”
